Turn Biotechnologies appoints Vittorio Sebastiano as head of research

Cell rejuvenation company Turn Biotechnologies has announced the appointment of co-founder Vittorio Sebastiano, PhD as head of research.

The company develops novel mRNA medicines to cure untreatable, age-related diseases.

Sebastiano led the development of Turn Bio’s ERA platform which produces tailored protein cocktails to rejuvenate cells.

Sebastiano, who assumes the new role this month, has served a chair of Turn Biotechnologies’ Scientific Advisory Board since he co-founded the company in 2018.

Turn Biotechnologies CEO, Anja Krammer, said:

“Vittorio’s vision and leadership will propel Turn Bio’s innovation and speed our efforts to develop new therapies.

“He keenly understands the potential our science has to redefine the way doctors treat age-related conditions, and shares our commitment to delivering a steady stream of new solutions to the clinic.”

Sebastiano said:

“The next months will be incredibly exciting, as we bridge the gap between academic science and the life-changing therapies so desperately needed by millions of people around the world.

“We have the potential to cure diseases that are currently untreatable, improve the quality of life for millions and truly transform and democratize medical care.”

VitaDAO invested $1 million in Turn Biotechnologies in July this year.

The company intends to use the funds to undertake preclinical efficacy testing of mRNA therapies to induce self-healing of the skin and eyes.